Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • RIAs Plan to Broaden Portfolios Beyond U.S., William Blair Investment Management Survey Finds

    Registered investment advisors increasingly view international and emerging markets exposure as essential to client portfolios and prefer active ETFs to access those markets, according to a new survey commissioned by William Blair Investment Management.

    Read more

  • Another Quarter, More Growth for Secondaries

    Despite persistent macro headwinds, momentum continues in the secondary market and industry insiders have adjusted their expectations upward yet again.

    Read more

  • Strengthening Financial Resilience in the Nonprofit Sector

    A recent William Blair event explored how planned giving, revenue diversification, and scenario planning can help organizations prepare for uncertainty and build for the future.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures